Commercial Channels

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, being regulatorily compliant, and the rapid advancements in artificial intelligence.

The Asembia AXS25 Summit strives to explore ways to improve patient outcomes, especially for rare and complex diseases.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Brett Casper explores the marketplace complexities that manufacturers face regularly.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s 2025 CGT forecasted approval goal.

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.

A crash course on the bubble itself, including therapeutic areas most affected.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

A panel dives into the current and future outlook of healthcare policies.

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

The conference’s opening keynote sets the scene for 2025 and the years to come.

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it.

It’s essential for commercial success, but presents its share of obstacles.